Chen Y, Zhang G G Z, Neilly J, Marsh K, Mawhinney D, Sanzgiri Y D
Abbott Laboratories, Global Pharmaceutical R&D, 1401 Sheridan Road, North Chicago, IL 60064, USA.
Int J Pharm. 2004 Nov 22;286(1-2):69-80. doi: 10.1016/j.ijpharm.2004.08.009.
Solid dispersions using Pluronic F-68 as a carrier were studied for improving the dissolution and bioavailability of ABT-963, a poorly water-soluble compound. The solid dispersions were prepared either by evaporation of the ethanol solutions containing ABT-963 and Pluronic, or by cooling the hot melt of the drug in the carrier. The dispersions were characterized using differential scanning calorimetry, powder X-ray diffractometry, scanning electron microscopy, elemental mapping, and by constructing the melting point phase diagram. In vitro dissolution and in vivo oral bioavailability in fasted dogs were compared for the solid dispersion and a conventional IR capsule formulation. Results showed that, at a composition of approximately 7.5%, ABT-963 formed a eutectic mixture with Pluronic F-68. Both the drug and the polymer were crystalline in the solid dispersion with a wide range of composition of each component. The solid dispersion substantially increased the in vitro dissolution rate of ABT-963. Dosing of the dispersion to fasted dogs resulted in a significant increase of oral bioavailability compared with the conventional IR capsule formulation. These results show that solid dispersion is a promising approach for developing ABT-963 drug products.
研究了以泊洛沙姆F-68为载体的固体分散体,以提高难溶性化合物ABT-963的溶出度和生物利用度。固体分散体通过蒸发含有ABT-963和泊洛沙姆的乙醇溶液,或通过冷却药物在载体中的热熔体来制备。使用差示扫描量热法、粉末X射线衍射法、扫描电子显微镜、元素映射以及构建熔点相图对分散体进行表征。比较了固体分散体和传统红外胶囊制剂在禁食犬体内的体外溶出度和体内口服生物利用度。结果表明,在约7.5%的组成下,ABT-963与泊洛沙姆F-68形成了低共熔混合物。在各组分组成范围较宽的固体分散体中,药物和聚合物均为结晶态。固体分散体显著提高了ABT-963的体外溶出速率。与传统红外胶囊制剂相比,将该分散体给禁食犬给药后,口服生物利用度显著提高。这些结果表明,固体分散体是开发ABT-963药物产品的一种有前景的方法。